Clinical trial finds that oral drug MK-0616 substantially reduces ‘bad’ cholesterol
MK-016 could offer another potential option to achieve guideline-recommended LDL-C levels resulting in reduction of cardiovascular risk.
Read MoreMK-016 could offer another potential option to achieve guideline-recommended LDL-C levels resulting in reduction of cardiovascular risk.
Read MoreReview the symposium highlights, visit the virtual poster session and meet the winners of the first Dr. Mark L. Entman Award for Excellence in Cardiovascular Education.
Read MoreBy Ana María Rodríguez, Ph.D. Patients with autoimmune disease have a higher risk of developing atherosclerosis and cardiovascular disease. Although studies have shown that human atherosclerotic
Read More